Patients are Sutro’s
passion and purpose.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. 

Our Sutro Story

Science designed to deliver ENDLESS OPPORTUNITY

Enabling a future where more is POSSIBLE.

Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience.

Explore opportunities

Join us and thrive in a team that values diversity and collaboration.

INVESTOR RESOURCES

NASDAQ: STRO

Stock Symbol

Press Releases

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference SOUTH SAN FRANCISCO, Calif., November 4, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company...

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML SOUTH SAN FRANCISCO, Calif., November 1, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage...

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical...